---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-282783"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:55:20.633561+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Graybug Q3 net loss $9.8M; terminates GB-102/401 programs, cuts 20 of 28 staff

## Summary
- Net loss $9.8M in Q3 2022 vs $8.0M in Q3 2021; nine-month loss $28.2M vs $27.1M.
- In August 2022, terminated 20 of 28 employees and wound down GB-102 (Phase 2b) and GB-401 programs; restructuring charge $2.4M.
- R&D expense fell to $3.2M from $4.0M due to program halt; G&A rose to $4.3M from $4.0M on stock-based compensation.
- Cash, equivalents, and short-term investments $43.6M; cash runway beyond 2023 subject to ongoing strategic review.

## SEC filing metadata
- accession: 0001193125-22-282783
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/d407208d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-282783
- JSON: https://secwatch.observer/filing/0001193125-22-282783.json
- Plain text: https://secwatch.observer/filing/0001193125-22-282783.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported the nine months ended September 30, 2022 results: net income $28.2 million.
  - Period: the nine months ended September 30, 2022
  - Net income: $28.2 million
  - Result: reported results
  source text: Net loss for the nine months ended September 30, 2022 was $28.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm
- Earnings Releases
  CalciMedica, Inc. reported the quarter ended September 30, 2022 results: net income $9.8 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $9.8 million
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2022 was $9.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.